Research programme: ubiquitin-modifying therapeutics - Boehringer Ingelheim/Mount Sinai Hospital/University Health Network/University of TorontoAlternative Names: Ubiquitin-binding variants - Boehringer Ingelheim
Latest Information Update: 06 Aug 2014
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Mount Sinai Hospital (Toronto); University Health Network; University of Toronto
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; CNS disorders; Diabetes mellitus; Inflammation